CN101410402A - 丁丙诺啡衍生物及其应用 - Google Patents
丁丙诺啡衍生物及其应用 Download PDFInfo
- Publication number
- CN101410402A CN101410402A CNA2007800108118A CN200780010811A CN101410402A CN 101410402 A CN101410402 A CN 101410402A CN A2007800108118 A CNA2007800108118 A CN A2007800108118A CN 200780010811 A CN200780010811 A CN 200780010811A CN 101410402 A CN101410402 A CN 101410402A
- Authority
- CN
- China
- Prior art keywords
- buprenorphine
- compound
- salt
- replaces
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (21)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0606124.6A GB0606124D0 (en) | 2006-03-28 | 2006-03-28 | Buprenorphine derivatives and uses thereof |
GB0606124.6 | 2006-03-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410318622.9A Division CN104151320A (zh) | 2006-03-28 | 2007-03-27 | 丁丙诺啡衍生物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101410402A true CN101410402A (zh) | 2009-04-15 |
Family
ID=36384277
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410318622.9A Pending CN104151320A (zh) | 2006-03-28 | 2007-03-27 | 丁丙诺啡衍生物及其应用 |
CNA2007800108118A Pending CN101410402A (zh) | 2006-03-28 | 2007-03-27 | 丁丙诺啡衍生物及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410318622.9A Pending CN104151320A (zh) | 2006-03-28 | 2007-03-27 | 丁丙诺啡衍生物及其应用 |
Country Status (21)
Country | Link |
---|---|
US (1) | US7964610B2 (zh) |
EP (1) | EP2001891B1 (zh) |
JP (1) | JP5167446B2 (zh) |
KR (1) | KR101430626B1 (zh) |
CN (2) | CN104151320A (zh) |
AU (1) | AU2007231133B2 (zh) |
BR (1) | BRPI0709157A8 (zh) |
CA (1) | CA2647417C (zh) |
DK (1) | DK2001891T3 (zh) |
ES (1) | ES2432169T3 (zh) |
GB (1) | GB0606124D0 (zh) |
IL (1) | IL193917A (zh) |
MX (1) | MX2008011984A (zh) |
MY (1) | MY151025A (zh) |
NZ (1) | NZ570997A (zh) |
PL (1) | PL2001891T3 (zh) |
PT (1) | PT2001891E (zh) |
RU (1) | RU2435773C2 (zh) |
TW (1) | TWI501969B (zh) |
WO (1) | WO2007110636A1 (zh) |
ZA (1) | ZA200807614B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108289887A (zh) * | 2015-10-26 | 2018-07-17 | 奥佛麦德公司 | 丁丙诺啡的乙二醇醚 |
CN116283893A (zh) * | 2023-03-22 | 2023-06-23 | 阜阳欣奕华制药科技有限公司 | 硫代羟基乙酸酐的制备方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008036980A1 (en) | 2006-09-22 | 2008-03-27 | Alltranz Inc. | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof |
ES2377599T3 (es) * | 2008-04-24 | 2012-03-29 | Janssen Pharmaceutica N.V. | Profármacos di-éster de nalmefeno |
FR2975912B1 (fr) | 2011-05-30 | 2013-06-14 | Flamel Tech Sa | Composition a liberation controlee de buprenorphine |
CA3016510A1 (en) | 2016-03-09 | 2017-09-14 | Indivior Uk Limited | Abuse-resistant pharmaceutical formulations |
AU2017325910B2 (en) * | 2016-09-13 | 2020-08-27 | Alar Pharmaceuticals Inc. | Sustained-release buprenorphine formulations |
WO2019064026A1 (en) | 2017-09-29 | 2019-04-04 | Orexo Ab | NEW PHARMACEUTICAL COMPOSITIONS |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
WO2023102489A1 (en) * | 2021-12-03 | 2023-06-08 | Board Of Regents Of The University Of Nebraska | Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
US5985880A (en) * | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
US5750534A (en) * | 1994-03-16 | 1998-05-12 | National Science Council | Nalbuphine esters having long acting analgesic action and method of use |
US6004969A (en) * | 1996-04-15 | 1999-12-21 | National Science Council | Transdermal delivery of buprenorphine preparations |
KR100204659B1 (ko) * | 1996-05-28 | 1999-06-15 | 강재헌 | 신규한 부프레노핀계 진통제용 화합물 |
US6225321B1 (en) * | 1997-06-05 | 2001-05-01 | Oliver Yoa-Pu Hu | Long analgesic acting nalbuphine polyester derivative and method of use |
EP1131059B1 (de) | 1998-11-13 | 2003-03-05 | Jago Research Ag | Trockenpulver zur inhalation |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
BR0108379A (pt) * | 2000-02-08 | 2002-11-05 | Euro Celtique Sa | Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
US7776314B2 (en) * | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20050186139A1 (en) * | 2002-10-25 | 2005-08-25 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US20050191244A1 (en) * | 2002-10-25 | 2005-09-01 | Gruenenthal Gmbh | Abuse-resistant pharmaceutical dosage form |
DE10250087A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10250084A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
ATE444296T1 (de) * | 2002-10-25 | 2009-10-15 | Euro Celtique Sa | Analoga und prodrugs von buprenorphin |
CN1263760C (zh) * | 2002-11-12 | 2006-07-12 | 财团法人奇美医院 | 新颖的丁丙诺啡酯衍生物及其制备方法,以及长效作用镇痛药学组合物 |
EP1422230B1 (en) | 2002-11-25 | 2007-12-26 | Chi Mei Foundation Medical Center | Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions |
JP2004175706A (ja) * | 2002-11-26 | 2004-06-24 | Chi Mei Foundation Medical Center | 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物 |
TW200500067A (en) * | 2003-01-21 | 2005-01-01 | Control Delivery Sys Inc | Salts of codrugs and uses related thereto |
WO2004071491A1 (en) * | 2003-02-04 | 2004-08-26 | Chrysalis Technologies Incorporated | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
US7195882B2 (en) * | 2003-06-03 | 2007-03-27 | Roche Diagnostics Operations, Inc. | Monoclonal antibodies specific for buprenorphine and metabolites thereof |
US7759358B2 (en) * | 2003-07-23 | 2010-07-20 | Crooks Peter A | Oral bioavailable prodrugs |
US7589233B2 (en) * | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
US7220842B2 (en) * | 2004-04-05 | 2007-05-22 | Dade Behring Inc. | Immunoassays for buprenorphine and norbuprenorphine |
-
2006
- 2006-03-28 GB GBGB0606124.6A patent/GB0606124D0/en not_active Ceased
-
2007
- 2007-03-27 PL PL07732177T patent/PL2001891T3/pl unknown
- 2007-03-27 ES ES07732177T patent/ES2432169T3/es active Active
- 2007-03-27 JP JP2009502210A patent/JP5167446B2/ja not_active Expired - Fee Related
- 2007-03-27 WO PCT/GB2007/001120 patent/WO2007110636A1/en active Application Filing
- 2007-03-27 AU AU2007231133A patent/AU2007231133B2/en not_active Ceased
- 2007-03-27 CN CN201410318622.9A patent/CN104151320A/zh active Pending
- 2007-03-27 PT PT77321776T patent/PT2001891E/pt unknown
- 2007-03-27 DK DK07732177.6T patent/DK2001891T3/da active
- 2007-03-27 RU RU2008142527/04A patent/RU2435773C2/ru not_active IP Right Cessation
- 2007-03-27 CN CNA2007800108118A patent/CN101410402A/zh active Pending
- 2007-03-27 US US12/294,462 patent/US7964610B2/en not_active Expired - Fee Related
- 2007-03-27 MY MYPI20083500 patent/MY151025A/en unknown
- 2007-03-27 CA CA2647417A patent/CA2647417C/en not_active Expired - Fee Related
- 2007-03-27 EP EP07732177.6A patent/EP2001891B1/en active Active
- 2007-03-27 NZ NZ570997A patent/NZ570997A/en not_active IP Right Cessation
- 2007-03-27 BR BRPI0709157A patent/BRPI0709157A8/pt not_active IP Right Cessation
- 2007-03-27 KR KR1020087023692A patent/KR101430626B1/ko not_active IP Right Cessation
- 2007-03-27 MX MX2008011984A patent/MX2008011984A/es active IP Right Grant
- 2007-03-27 TW TW096110534A patent/TWI501969B/zh not_active IP Right Cessation
-
2008
- 2008-09-04 ZA ZA200807614A patent/ZA200807614B/xx unknown
- 2008-09-04 IL IL193917A patent/IL193917A/en not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108289887A (zh) * | 2015-10-26 | 2018-07-17 | 奥佛麦德公司 | 丁丙诺啡的乙二醇醚 |
CN116283893A (zh) * | 2023-03-22 | 2023-06-23 | 阜阳欣奕华制药科技有限公司 | 硫代羟基乙酸酐的制备方法 |
CN116283893B (zh) * | 2023-03-22 | 2024-04-26 | 阜阳欣奕华制药科技有限公司 | 硫代羟基乙酸酐的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0709157A2 (pt) | 2011-06-28 |
US20100234412A1 (en) | 2010-09-16 |
AU2007231133A2 (en) | 2008-10-16 |
KR20080105124A (ko) | 2008-12-03 |
CA2647417A1 (en) | 2007-10-04 |
ES2432169T3 (es) | 2013-12-02 |
JP2009531406A (ja) | 2009-09-03 |
TWI501969B (zh) | 2015-10-01 |
MY151025A (en) | 2014-03-31 |
MX2008011984A (es) | 2008-10-03 |
EP2001891B1 (en) | 2013-07-24 |
BRPI0709157A8 (pt) | 2018-04-24 |
JP5167446B2 (ja) | 2013-03-21 |
KR101430626B1 (ko) | 2014-08-18 |
AU2007231133A8 (en) | 2011-08-25 |
NZ570997A (en) | 2011-08-26 |
AU2007231133A1 (en) | 2007-10-04 |
AU2007231133B2 (en) | 2011-09-01 |
DK2001891T3 (da) | 2013-11-04 |
PL2001891T3 (pl) | 2014-03-31 |
EP2001891A1 (en) | 2008-12-17 |
CA2647417C (en) | 2014-09-23 |
US7964610B2 (en) | 2011-06-21 |
CN104151320A (zh) | 2014-11-19 |
IL193917A (en) | 2014-12-31 |
RU2008142527A (ru) | 2010-05-10 |
WO2007110636A1 (en) | 2007-10-04 |
GB0606124D0 (en) | 2006-05-03 |
TW200806672A (en) | 2008-02-01 |
PT2001891E (pt) | 2013-10-30 |
ZA200807614B (en) | 2009-10-28 |
RU2435773C2 (ru) | 2011-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101410402A (zh) | 丁丙诺啡衍生物及其应用 | |
EP2530079A1 (en) | Phenyl c-glucoside derivatives, preparation methods and uses thereof | |
CN103180327A (zh) | 稠环的4-氨基嘧啶及其作为可溶性鸟甘酸环化酶的刺激物的用途 | |
US4599355A (en) | Treatment of sleep disorders | |
WO2018068429A1 (zh) | 左旋四氢帕马汀氘代衍生物及其医药用途 | |
CN110563679A (zh) | 一种倍半萜内酯类化合物及其制备方法和在制备防治鼻咽癌的药物中的应用 | |
JP2003520231A (ja) | 鎮痛剤としてのデクルシノール(Decursinol)またはその誘導体 | |
CN111518157B (zh) | 一种雷公藤甲素衍生物及其制备方法和应用 | |
EP2438047B1 (en) | Antagonism of human formyl peptide receptor for treatment of disease | |
AU777920B2 (en) | Beta-D-5-thioxylose derivatives, preparation method and therapeutic use | |
JPH0952899A (ja) | ロイコトリエン拮抗剤 | |
JPS6352012B2 (zh) | ||
JPH0867627A (ja) | 肝疾患治療用組成物 | |
JPH07173188A (ja) | 新規アリソールおよびアリソール類を有効成分とする脳機能改善剤 | |
WO2022122042A1 (zh) | 阿比特龙衍生物及其制备方法 | |
KR101119968B1 (ko) | 베타락톤계 화합물 또는 이의 약학적으로 허용가능한 염 및이를 유효성분으로 함유하는 항비만용 약학적 조성물 | |
JP2001316260A (ja) | カバラクトン類を有効成分とするTNF−α産生抑制剤 | |
JPH0625089B2 (ja) | ジアルカノイルオキシベンジリデンジアルカノエ−ト | |
JPH07179487A (ja) | 新規キサントン配糖体およびその用途 | |
JPH07206672A (ja) | 医薬組成物および処置法 | |
JPH092950A (ja) | 医薬組成物および処置法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1130259 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: RB MEDICAL LTD. Free format text: FORMER OWNER: RECKITT BENCKISER HEALTHCARE (UK) LIMITED Effective date: 20121218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20121218 Address after: Burke County, England Applicant after: RECKITT BENCKISER HEALTHCARE (UK) LIMITED Address before: Burke County, England Applicant before: Reckitt & Benksl Health-Care (England) Ltd. |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20090415 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1130259 Country of ref document: HK |